BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 34980505)

  • 1. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.
    De Silvestro G; Marson P; La Raja M; Cattelan AM; Guarnieri G; Monticelli J; Tiberio I; Vianello A; Gandini G; Gessoni G; Fiorin F; Sardella C; Astolfi L; Saia M;
    Eur J Intern Med; 2022 Mar; 97():42-49. PubMed ID: 34980505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): An organizational model for future emergencies.
    De Silvestro G; Gandini G; Fiorin F; Marson P; Barbone E; Frigato A; Gessoni G; Veronesi A; Pacenti M; Castelli M; Rinaldi M; Rizzi M; Stefani F; Roveroni G
    Transfus Apher Sci; 2021 Aug; 60(4):103154. PubMed ID: 33994107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trial".
    Teofili L; Landolfi R; Cingolani A; Antinori A; Vecchiet J; Sanguinetti M; Gasbarrini A; Pasciuto T; Orlando N; Lamonica S
    Trials; 2020 Oct; 21(1):875. PubMed ID: 33092632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
    Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
    Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced Mortality among COVID-19 ICU Patients after Treatment with HemoClear Convalescent Plasma in Suriname.
    Bihariesingh-Sanchit R; Bansie R; Ramdhani N; Mangroo R; Bustamente D; Diaz E; Fung A Foek C; Thakoer I; Vreden S; Choudhry Z; van 't Wout AB; Diavatopoulos DA; Nierich AP
    mBio; 2023 Apr; 14(2):e0337922. PubMed ID: 36815780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial.
    Bégin P; Callum J; Heddle NM; Cook R; Zeller MP; Tinmouth A; Fergusson DA; Cushing MM; Glesby MJ; Chassé M; Devine DV; Robitalle N; Bazin R; Shehata N; Finzi A; McGeer A; Scales DC; Schwartz L; Turgeon AF; Zarychanski R; Daneman N; Carl R; Amorim L; Gabe C; Ellis M; Sachais BS; Loftsgard KC; Jamula E; Carruthers J; Duncan J; Lucier K; Li N; Liu Y; Armali C; Kron A; Modi D; Auclair MC; Cerro S; Avram M; Arnold DM
    Trials; 2021 May; 22(1):323. PubMed ID: 33947446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia.
    Bar KJ; Shaw PA; Choi GH; Aqui N; Fesnak A; Yang JB; Soto-Calderon H; Grajales L; Starr J; Andronov M; Mastellone M; Amonu C; Feret G; DeMarshall M; Buchanan M; Caturla M; Gordon J; Wanicur A; Monroy MA; Mampe F; Lindemuth E; Gouma S; Mullin AM; Barilla H; Pronina A; Irwin L; Thomas R; Eichinger RA; Demuth F; Luning Prak ET; Pascual JL; Short WR; Elovitz MA; Baron J; Meyer NJ; Degnan KO; Frank I; Hensley SE; Siegel DL; Tebas P
    J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34788233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study.
    Senefeld JW; Johnson PW; Kunze KL; Bloch EM; van Helmond N; Golafshar MA; Klassen SA; Klompas AM; Sexton MA; Diaz Soto JC; Grossman BJ; Tobian AAR; Goel R; Wiggins CC; Bruno KA; van Buskirk CM; Stubbs JR; Winters JL; Casadevall A; Paneth NS; Shaz BH; Petersen MM; Sachais BS; Buras MR; Wieczorek MA; Russoniello B; Dumont LJ; Baker SE; Vassallo RR; Shepherd JRA; Young PP; Verdun NC; Marks P; Haley NR; Rea RF; Katz L; Herasevich V; Waxman DA; Whelan ER; Bergman A; Clayburn AJ; Grabowski MK; Larson KF; Ripoll JG; Andersen KJ; Vogt MNP; Dennis JJ; Regimbal RJ; Bauer PR; Blair JE; Buchholtz ZA; Pletsch MC; Wright K; Greenshields JT; Joyner MJ; Wright RS; Carter RE; Fairweather D
    PLoS Med; 2021 Dec; 18(12):e1003872. PubMed ID: 34928960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19.
    Briggs N; Gormally MV; Li F; Browning SL; Treggiari MM; Morrison A; Laurent-Rolle M; Deng Y; Hendrickson JE; Tormey CA; Desruisseaux MS
    PLoS One; 2021; 16(7):e0254453. PubMed ID: 34320004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of COVID-19 Patients with Two Units of Convalescent Plasma in a Resource-Constrained State.
    Ipe TS; Ugwumba B; Spencer HJ; Le T; Ridenour T; Armitage J; Ryan S; Pearson S; Kothari A; Patil N; Dare R; Crescencio JCR; Venkata A; Laudadio J; Mohammad K; Jamal N; Thompson J; McNew H; Gibbs M; Hennigan S; Kellar S; Reitzel K; Walser BE; Novak A; Quinn B
    Lab Med; 2022 Nov; 53(6):623-628. PubMed ID: 35771890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial.
    Menichetti F; Popoli P; Puopolo M; Spila Alegiani S; Tiseo G; Bartoloni A; De Socio GV; Luchi S; Blanc P; Puoti M; Toschi E; Massari M; Palmisano L; Marano G; Chiamenti M; Martinelli L; Franchi S; Pallotto C; Suardi LR; Luciani Pasqua B; Merli M; Fabiani P; Bertolucci L; Borchi B; Modica S; Moneta S; Marchetti G; d'Arminio Monforte A; Stoppini L; Ferracchiato N; Piconi S; Fabbri C; Beccastrini E; Saccardi R; Giacometti A; Esperti S; Pierotti P; Bernini L; Bianco C; Benedetti S; Lanzi A; Bonfanti P; Massari M; Sani S; Saracino A; Castagna A; Trabace L; Lanza M; Focosi D; Mazzoni A; Pistello M; Falcone M;
    JAMA Netw Open; 2021 Nov; 4(11):e2136246. PubMed ID: 34842924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study.
    Bartelt LA; Markmann AJ; Nelson B; Keys J; Root H; Henderson HI; Kuruc J; Baker C; Bhowmik DR; Hou YJ; Premkumar L; Cornaby C; Schmitz JL; Weiss S; Park Y; Baric R; de Silva AM; Lachiewicz A; Napravnik S; van Duin D; Margolis DM
    mBio; 2022 Oct; 13(5):e0175122. PubMed ID: 36135380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Multicenter, Prospective, Observational, Cohort-Controlled Study of Clinical Outcomes Following Coronavirus Disease 2019 (COVID-19) Convalescent Plasma Therapy in Hospitalized Patients With COVID-19.
    Chauhan L; Pattee J; Ford J; Thomas C; Lesteberg K; Richards E; Bernas CA; Loi M; Dumont L; Annen K; Berg M; Zirbes M; Knight V; Miller A; Jenkins TC; Bennett TD; Monkowski D; Boxer RS; Beckham JD
    Clin Infect Dis; 2022 Aug; 75(1):e466-e472. PubMed ID: 34549274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.